Author

Dirk Lindner 1

1 Takeda Pharmaceuticals, Zurich, Switzerland

COMPARISON OF CLINICAL IMPROVEMENT AS MEASURED BY TWO QUALITY-OF-LIFE INDEXES: A POOLED ANALYSIS OF VEDOLIZUMAB RANDOMIZED CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE

Edouard Louis, Pravin Kamble, Dirk Lindner, Christian Agboton

DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS

Stefan Schreiber, Silvio Danese, Laurent Peyrin-Biroulet, Jean-Frederic Colombel, Bruce E. Sands, Dirk Lindner, Richard A. Lirio, Christian Agboton, Edward V. Loftus Jr.

EFFICACY AND SAFETY OF INTRAVENOUS VEDOLIZUMAB FOR TREATMENT OF CHRONIC POUCHITIS: RESULTS OF THE PHASE 4 EARNEST TRIAL

Simon Travis, Mark S. Silverberg, Silvio Danese, Paolo Gionchetti, Mark Lowenberg, Dirk Lindner, Armella Escher, Stephen Jones, Bo Shen

MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS

Vipul Jairath, Brian G. Feagan, Mark S. Silverberg, Silvio Danese, Paolo Gionchetti, Mark Lowenberg, Brian Bressler, Marc Ferrante, Ailsa L Hart, Dirk Lindner, Armella Escher, Stephen Jones, Bo Shen, Simon Travis

REAL-WORLD EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A POOLED MULTICENTRE OBSERVATIONAL COHORT ANALYSIS OF CLINICAL AND MODELED PHARMACOLOGICAL DATA

Niels Vande Casteele, William Sandborn, Brian G. Feagan, Severine Vermeire, Parambir Dulai, Julian Panés, Andres Yarur, Xavier Roblin, Shomron Ben-Horin, Iris Dotan, Mark Osterman, Dirk Lindner, Christian Agboton, Maria Rosario, Teresa Osborn

Item 1 - 5 / 5
1